The Lancet Neurology publishes positive results of AFFiRiS' Phase 1 trial with PD01A in Parkinson’s disease patients
- Written by Reporters
- Repeated immunisation with PD01A is safe and well-tolerated over an extended time period
- Active immunisation with PD01A resulted in a substantial aSyn-specific antibody response and memory effect
- This antibody response was associated with a substantial reduction in CSF oligomeric aSyn protein
- Results represent long-term data from a first-in-human...